Trial reportEuropean radiology2013
MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation.
Trial report in European radiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.European journal of nuclear medicine and molecular imaging · 2022Guideline
- Holmium-166 radioembolisation dosimetry in HCC.European journal of nuclear medicine and molecular imaging · 2025Trial
- Safety and Efficacy ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Trial
- Additional hepaticBMC gastroenterology · 2018Trial
- Ultrasound contrast microbubbles to predict the microsphere distribution during transarterial radioembolization with holmium microspheres, an in vitro proof of concept study.Drug delivery · 2025Article
- Article
- Development and validation of an innovative administration system to facilitate controlled holmium-166 microsphere administration during TARE.EJNMMI physics · 2024Article
- Quantitative CT imaging and radiation-absorbed dose estimations ofEuropean radiology experimental · 2024Article
- Accuracy of holmium-166 SPECT/CT quantification over a large range of activities.EJNMMI physics · 2024Article
- The Deterioration of Sarcopenia Post-Transarterial Radioembolization with Holmium-166 Serves as a Predictor for Disease Progression at 3 Months in Patients with Advanced Hepatocellular Carcinoma: A Pilot Study.Journal of personalized medicine · 2024Article
- Transarterial Radioembolization: Overview of Radioembolic Devices.Seminars in interventional radiology · 2023Review
- A Theranostic Approach in SIRT: Value of Pre-Therapy Imaging in Treatment Planning.Journal of clinical medicine · 2022Review
- Holmium-166 Radioembolization: Current Status and Future Prospective.Cardiovascular and interventional radiology · 2022Review
- Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery.European journal of nuclear medicine and molecular imaging · 2022Article
- Intratumoral injection of holmium-166 microspheres as neoadjuvant therapy of soft tissue sarcomas in dogs.Frontiers in veterinary science · 2022Article
- Development of an MRI-Guided Approach to Selective Internal Radiation Therapy Using Holmium-166 Microspheres.Cancers · 2021Article
- Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects.Molecules (Basel, Switzerland) · 2021Review
- Case Report: Radioactive Holmium-166 Microspheres for the Intratumoral Treatment of a Canine Pituitary Tumor.Frontiers in veterinary science · 2021Article
- Yttrium-90 TOF-PET-Based EUD Predicts Response Post Liver Radioembolizations Using Recommended Manufacturer FDG Reconstruction Parameters.Frontiers in oncology · 2021Article
- The superior predictive value ofEuropean journal of nuclear medicine and molecular imaging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo demonstrate the feasibility of MRI-based assessment of the intrahepatic Ho-PLLA-MS biodistribution after radioembolisation in order to estimate the absorbed radiation dose.
methodsFifteen patients were treated with holmium-166 ((166)Ho) poly(L-lactic acid)-loaded microspheres (Ho-PLLA-MS, mean 484 mg; range 408-593 mg) in a phase I study. Multi-echo gradient-echo MR images were acquired from which R (2) maps were constructed. The amount of Ho-PLLA-MS in the liver was determined by using the relaxivity r (2) of the Ho-PLLA-MS and compared with the administered amount. Quantitative single photon emission computed tomography (SPECT) was used for comparison with MRI regarding the whole liver absorbed radiation dose.
resultsR (2) maps visualised the deposition of Ho-PLLA-MS with great detail. The mean total amount of Ho-PLLA-MS detected in the liver based on MRI was 431 mg (range 236-666 mg) or 89 ± 19 % of the delivered amount (correlation coefficient r = 0.7; P < 0.01). A good correlation was found between the whole liver mean absorbed radiation dose as assessed by MRI and SPECT (correlation coefficient r = 0.927; P < 0.001).
conclusionMRI-based dosimetry for holmium-166 radioembolisation is feasible. Biodistribution is visualised with great detail and quantitative measurements are possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.